Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease

Optimum Perspectives
05/08/2025 23 min Episodio 34
Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease

Listen "Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease"

Descargar episodio Ver en sitio original

Episode Synopsis

The latest episode of Optimum Perspectives Podcast has just dropped, featuring LoQus23 Therapeutics’ Chief Scientific Officer and founder Caroline Benn! Listen as Caroline details the devastating effects of Huntington’s Disease on patients and families, her personal motivations for working in this therapeutic area, as well as LoQus23’s unique approach to battling the disease through their innovative small molecule approach. Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Optimum Perspectives

Q&A with Professor Ali Tavassoli of Curve Therapeutics: RSC Interdisciplinary Prize winner 2025 25/06/2025
Stronger together: changing the future of muscle wasting condition 28/02/2025
How bioengineered spider silk-based proteins are changing the world 06/02/2025
How to have a perfect IPO on NASDAQ 23/01/2025
Ariceum Therapeutics: Pioneering research into next-generation radiopharmaceutical therapy targeting hard-to-treat cancers 27/11/2024
Kling Biotherapeutics: Using B cell tech to discover new targets and antibodies in cancer 21/11/2024
DISCO Pharmaceuticals looks to unlock new drugs with “surfaceome” technology 05/11/2024
SpliceBio: Celebrating progress in ophthalmology research on World Sight Day 10/10/2024
Heidelberg Pharma – turning deadly mushroom toxin into cancer medicine 12/09/2024
Resolution Therapeutics: pioneering macrophage therapies for liver diseases 08/08/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA